Logo

Chugai's Risdiplam Receives MHLW's Orphan Drug Designation for Spinal Muscular Atrophy (SMA)

Share this

Chugai's Risdiplam Receives MHLW's Orphan Drug Designation for Spinal Muscular Atrophy (SMA)

Shots:

  • The MHLW’s ODD follows P-II/III (FIREFISH- SUNFISH) study assessing Risdiplam in patients with  spinal muscular atrophy (SMA) in Japan
  •  Chugai & Roche collaborated for the clinical development Risdiplam- first oral systemic therapy for SMA
  • Risdiplam (RG7916) is survival motor neuron-2 (SMN2) splicing modifier targeted to increase SMN protein levels in CNS and has received ODD in EU- Switzerland & the US- FDA’s FT designation- EMA’s PRIME designation in Dec’18. In 2020 Chugai also plans to file a regulatory application for risdiplam in Japan

  Ref: Chugai | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions